ISRACANN BIOSCIENCES INC - ISCNF STOCK NEWS

Isracann Biosciences announced that its audited annual financial statements for the year ending May 31, 2022, were not filed by the September 28, 2022 deadline due to unforeseen delays related to their audit process. These delays stemmed from the recent acquisition of operations in Israel and Canada, affecting consolidation efforts. The company expects to file the necessary documents within the next seven weeks. A management cease trade order has been issued, affecting only the company's management while allowing other securityholders to continue trading.

Isracann Biosciences (OTC: ISCNF) announces the successful shipment of Canadian cannabis genetics to Israel, marking a significant step in its operations. The genetics include strains Liberty Haze, Hell Monkey, and Grape Stomper, which have shown strong consumer demand in Canada. This integration into the Israeli market aims to provide premium cannabis products domestically. With strategic cooperation from United Greeneries, the company plans to scale production efficiently and position itself as a low-cost, high-quality cannabis supplier.

Isracann Biosciences (OTC: ISCNF) has announced its first shipment of cannabis strains to Israel, marking a significant step in its collaboration with United Greeneries Ltd and Intelicanna. This agreement includes three premium cannabis strains and a revenue-sharing model, where United Greeneries handles cultivation and genetics. CEO Phil Floucault highlights Israel's status as the largest importer of Canadian cannabis, emphasizing the demand for high THC strains. The shipment is expected to enhance local production capabilities in Israel.

Isracann Biosciences Inc. (CSE: IPOT, OTC: ISCNF) has signed a distribution agreement with Pure Integrative Pharmacy to promote its Praesidio Health products in Canada. CEO Phil Floucault expressed excitement over this milestone, which aims to introduce natural health products (NHPs) to consumers. Praesidio is focused on developing evidence-based NHPs addressing various health issues and has submitted formulations for Health Canada approval. This agreement marks the company's commitment to expanding its distribution across North America, with products expected to be on the market by Q4 2022.

Isracann Biosciences has successfully closed the first tranche of its non-brokered private placement, issuing 4,679,600 units at $0.05 each, resulting in gross proceeds of $233,980. Each unit consists of one common share and one warrant, the latter allowing purchase of additional shares at $0.055 for 48 months. Proceeds will be allocated for product development and general operations. All issued securities are subject to a four-month hold period, ending December 3, 2022. The offering is not registered under the U.S. Securities Act.

Isracann Biosciences (OTC: ISCNF) announced that its subsidiary, Praesidio Health, has submitted NPN applications for natural health products to Health Canada. This submission is expected to expedite approvals due to their natural ingredients. The formulations aim to address chronic conditions, including post-viral syndrome and generalized anxiety, potentially becoming first-line treatments. Isracann's CEO expressed optimism regarding near-term revenue generation from these products, targeting Q4 2022 for market readiness in Canada and the USA.

Isracann Biosciences (OTC: ISCNF) has announced the expansion of its leadership team following its acquisition of Praesidio Health Inc. This strategic move aims to enhance the integration of natural health medicine (NHM) R&D to achieve its revenue goals in 2022. Key appointments include Mr. James (JT) Thompson as Chief Operations Officer, Mr. Matt Chatterton as Chief Science Officer, and Mr. Stephen Parker as VP of Business Development. Additionally, the company plans a non-brokered private placement of up to 50 million units at $0.06 each, potentially raising $3 million for product development and operations.

Isracann Biosciences has successfully completed the acquisition of Praesidio Health for C$4,000,000 in common shares. Praesidio will function as a wholly-owned subsidiary focused on developing natural health products (NHPs) for various health issues. The acquisition includes staggered share issuances, with an initial issuance valued at C$1,000,000. Key appointments include Dr. George Vrabec and Bob Mehr, enhancing Isracann's capabilities in NHP development. Isracann aims to expand its market presence and revenue generation strategies across North America and Europe through this strategic acquisition.

Isracann Biosciences has announced a definitive agreement to acquire Praesidio Health for C$4,000,000 in common shares. The transaction includes the issuance of the Consideration Shares in seven tranches, starting with C$1,000,000 at closing. Praesidio will operate as a wholly-owned subsidiary, developing natural health medicine (NHM) products. The closing is subject to regulatory approvals and is expected around April 4, 2022. This acquisition aims to enhance Isracann's product development capabilities and expand its market reach into Europe.